Menu

Blog

Apr 18, 2020

Seeking COVID-19’s New Hope in Scripps Research’s Collection of Old Drugs

Posted by in category: biotech/medical

In an effort to find an effective antiviral drug against SARS-CoV-2. Calibr, the drug development division of Scripps Research, is leveraging a unique resource—the ReFRAME drug collection. The ReFRAME drug collection comprises over 14,000 compounds that have been approved by the FDA for other diseases. A medicine identified from this resource could be rapidly repurposed.

Leave a reply